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Background: Quality of life (QOL) is an important outcome measure in the treatment of heroin addiction. The
Taiwan version of the World Health Organization Quality of Life assessment (WHOQOL-BREF [TW]) has been
developed and studied in various groups, but not specifically in a population of injection drug users. The aim of
this study was to analyze the psychometric properties of the WHOQOL-BREF (TW) in a sample of injection drug
users undergoing methadone maintenance treatment.
Methods: A total of 553 participants were interviewed and completed the instrument. Item-response distributions,
internal consistency, corrected item-domain correlation, criterion-related validity, and construct validity through
confirmatory factor analysis were evaluated.
Results: The frequency distribution of the 4 domains of the WHOQOL-BREF (TW) showed no floor or ceiling effects.
The instrument demonstrated adequate internal consistency (Cronbach’s alpha coefficients were higher than 0.7 across
the 4 domains) and all items had acceptable correlation with the corresponding domain scores (r = 0.32-0.73).
Correlations (p < 0.01) of the 4 domains with the 2 benchmark items assessing overall QOL and general health were
supportive of criterion-related validity. Confirmatory factor analysis yielded marginal goodness-of-fit between the
4-domain model and the sample data.
Conclusions: The hypothesized WHOQOL-BREF measurement model was appropriate for the injection drug users after
some adjustments. Despite different patterns found in the confirmatory factor analysis, the findings overall suggest that
the WHOQOL-BREF (TW) is a reliable and valid measure of QOL among injection drug users and can be utilized in future
treatment outcome studies. The factor structure provided by the study also helps to understand the QOL characteristics
of the injection drug users in Taiwan. However, more research is needed to examine its test-retest reliability and
sensitivity to changes due to treatment.
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Injecting use of heroin has been a risk factor for acquiring
infectious diseases, including the human immunodefi-
ciency virus (HIV) and hepatitis C virus (HCV) [1]. In
Taiwan, it is estimated that 34% of the HIV cases are injec-
tion drug users (IDUs) [2]. To stem the spread of HIV,
methadone maintenance treatment (MMT) was adopted
in 2006 in Taiwan. Studies evaluating the efficacy and ef-
fectiveness of MMT have been centered on the objective
outcome criteria, such as retention, death, heroin use, and
crime rates [3]. However, it is not clear how IDU perceive
the effects of treatment and, in particular, how treatments
have impacted their quality of life [4]. Drug abuse or de-
pendence is associated with multiple negative conse-
quences physically and mentally as well as in social
relations and work [5]. Although methadone alleviates the
physical symptoms of opioid dependence [6], how it im-
pacts the quality of life of IDUs remains to be evaluated.
Therefore, it is important to consider subjective patients’
perception in the assessment of harm reduction programs
by means of self-reported measures [7,8].
Because heroin addiction is a chronic and relapsing
condition, which causes substantial impairments in both
the physical and psychosocial health of the patients,
the quality of life (QOL) scales have been used as an
outcome measure to evaluate and to quantify the changes
in patients’ functioning and well-being during treatment
[9,10]. The generic QOL instruments commonly used in
the MMT-related studies include the Nottingham Health
Profile (e.g., [11,12]), the Quality of Well-Being Scale (e.g.,
[13]), the Medical Outcomes Study 36-Item Short-Form
Health Survey (e.g., [14,15]), and the short version of the
World Health Organization Quality of Life assessment
(WHOQOL-BREF) (e.g., [16,17]). Of these generic QOL
measures, only the WHOQOL is developed by first es-
tablishing the definition of subjective QOL as ‘an indi-
vidual’s perception of their position in life in the context
of the culture and value systems in which they live, and
in relation to their goals, expectations, standards and
concerns’ [18-20].
The WHOQOL contains 100 items (WHOQOL-100)
[20]. To minimize the burden of the respondents and to
ameliorate time constraint, a shortened, 26-item ver-
sion, the WHOQOL-BREF, was developed [21]. The
WHOQOL-BREF was translated for use in Taiwan
(TW) according to the WHO international guidelines
[22], and shown to have good test-retest reliability, in-
ternal consistency, content and discriminant validity
[23]. The psychometric properties of the WHOQOL-
BREF (TW) have been explored earlier (e.g., [24-26]).
For example, Chen et al. [24] demonstrated adequate
reliability and validity of the WHOQOL-BREF (TW)
and that suggested that it may be used as a health indi-
cator in different age groups from early adolescence toadulthood. In addition, it has been demonstrated that
the instrument is suitable for the assessment of health
status perceived by persons with spinal cord injury [27]
and hemodialysis patients [28].
However, to our knowledge, few studies to date have
provided evidence of the reliability and validity of the
WHOQOL-BREF (TW) in IDUs enrolled in a MMT pro-
gram. In order to use the instrument with the IDUs, the
suitability of the WHOQOL-BREF (TW) needs to be vali-
dated prior to its clinical application to this population
group [29]. The purpose of the present study was there-
fore to examine the item-response distribution, internal
consistency, corrected item-domain correlation, criterion-
related validity, and construct validity of the WHOQOL-
BREF (TW) in IDUs under MMT.
Methods
Participants and procedure
A total of 599 eligible participants who fulfilled the
Diagnostic and Statistical Manual of Mental Disorders
(DSM) version IV criteria for heroin abuse from 4
methadone outpatient clinics in northern Taiwan were
invited during the years 2008 and 2009 to participate
in the study. Ethics approval for this study was obtained
from the Institutional Review Board of Human Subjects
Protection at the Taipei Medical University (P960205)
and the Taipei City Hospital (TCHIRB-970404-E). 553
participants were interviewed and 46 withdrew their par-
ticipation without signing the consent. All participants
met the following eligibility criteria: heroin abuse/de-
pendence, enrolled in methadone outpatient treatment,
aged 18 or above and being able to read. They were en-
rolled in a MMT program at the time of interview. After
completion, participants were reimbursed for $100 New
Taiwan dollars (approximately 3 US dollars).
Outcome measure
The self-administered WHOQOL-BREF (TW) (Additional
file 1) contains 28 items, including 2 benchmark items
assessing overall QOL and general health [22]. The
remaining 26 items consist of 24 standard items from
the original WHOQOL-BREF in 4 domains: physical
health, psychological health, social relationships, and
environment, plus 2 culturally relevant items: “Do you
feel respected by others?” (social relationships domain),
and “Are you usually able to get the things you like to
eat?” (environment domain).
Scoring of the WHOQOL-BREF (TW) concerns “how
good”, “how satisfied”, “how completely”, “how often” or
“how much” the participant felt in the last 2 weeks and is
rated on a 5-point Likert scale. The 2 benchmark items
(overall QOL and general health) were calculated as a sin-
gle score with a range of 1-5. Domain scores were calcu-
lated by multiplying the mean score for all items included
Table 1 Demographic and clinical characteristics of the
participants (n = 510)
Characteristics Mean (S.D.)
Age groups (year) 40.7 (9.1)
Duration of heroin use (years) 11.96 (7.78)
Average MMT dose (mg/day) 51.62 (32.40)






Less than 9 years 133 (26.1)
At least 9 years 371 (72.7)








Missing replies 20 (3.9)
SD: standard deviation; HCV: hepatitis C virus; HIV: human
immunodeficiency virus.
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scores for each domain range from 4 to 20, with higher
scores indicating better QOL.
Data analysis
Descriptive analysis was used to report the demographic
and clinical characteristics of the participants. The re-
sponse distributions of domain and item scores were cal-
culated to identify problematic items. Floor and ceiling
effects were considered significant if the percentage of
participants achieving the lowest and the highest scores
exceeds 20% of the total sample [30]. To test reliability,
the Cronbach’s alpha coefficient was used to evaluate
the internal consistency of each domain of the WHOQOL-
BREF (TW). Cronbach’s alpha values equal to or greater
than 0.70 were considered satisfactory [31]. The corrected
item-domain correlation was also reported to examine the
homogeneity of the items in each domain. The criterion-
related validity of the WHOQOL-BREF (TW) was evalu-
ated by measuring the strength of Pearson’s r correlation
between each item/domain scores and two criteria (i.e.,
overall QOL and general health). The strength of rela-
tionship of 0.40 or above was considered satisfactory
(r ≥ 0.81-1.0 as excellent, 0.61-0.80 very good, 0.41-0.60
good, 0.21-0.40 fair and ≤ 0.20 poor) [31].
For construct validity, confirmatory factor analysis
based on a maximum likelihood estimate, was con-
ducted to validate whether the existing domain struc-
ture could be fit to the IDUs enrolled in a methadone
treatment program while controlling for age, education,
gender, HIV, HCV, duration of heroin use, methadone
dose and days in MMT at study interview. The goodness-
of-fit indicators include: the comparative fit index (CFI)
and the non-normed fit index (NNFI) with values above
0.90 as well as the root mean square error of approxima-
tion (RMSEA) with values lower than 0.08 [32]. Model
modifications were performed when the modification
index suggests adding an error covariance between two
items or adding a path from domain to item. Based on the
two indices, the suggestion, with the greatest decrease in
chi-square value, was selected to modify the model until
the above criteria (CFI > 0.90, NNFI > 0.90, and RMSEA <
0.08) were met [33].
Results
Characteristics of the participants
Of participants, 510 completed the WHOQOL-BREF
(TW) in a private room at the clinic of about 15 minutes
and used in the analysis. The data of 43 patients were ex-
cluded from further analysis because they did not respond
to all WHOQOL-BREF questions. Table 1 shows the
demographic and clinical characteristics of these 510 par-
ticipants. The mean age of the participants was 40.7
(standard deviation [SD] = 9.1) and mean duration ofheroin use was 11.96 years (SD = 7.78). The average
methadone dose was 51.62 mg/day (SD = 32.4) and mean
duration of participating in the MMT was 183.86 days
(SD = 150.90). Most were males (86.9%). The majority of
the participants (72.7%) had completed at least 9 years of
compulsory schooling; 12% were HIV positive and over
85% were HCV positive.
Score distributions
As indicated in Table 2, the floor and ceiling effects in
each domain score was low (0%-1.0%). For all WHOQOL-
BREF (TW) items, the percentage of lowest and highest
scores was, in general, below 20%. However, floor effects
for the positive feelings facet (20.0%) and for the financial
resources facet (21.2%) were observed. In addition, a ceil-
ing effect for the dependence on medication or treatment
facet (24.5%) was notable.Reliability
The estimated values of Cronbach’s alpha for the physical
health, psychological health, social relationships, and envir-
onment domains were 0.79, 0.78, 0.76, and 0.87 (Table 2),
respectively, confirming adequate internal consistency of
the instrument. On corrected item-domain correlation, all
Table 2 Internal consistency and score distribution of the
WHOQOL-BREF (TW) in IDU (n = 510)




Overall quality of life 2.7 3.3
General health 4.1 2.0
Physical health domain 0.79 0.0 0.2




Energy and fatigue 4.9 4.7
Mobility 4.3 9.4
Sleep and rest 7.5 3.5
Activities of daily living 1.8 3.5
Working capacity 3.1 5.1
Psychological health domain 0.78 0.0 0.0
Positive feelings 20.0 1.2




Body image and appearance 3.7 12.5
Self-satisfaction 4.3 6.9
Negative feelings 6.5 3.9
Social relationships domain 0.76 0.8 1.0
Personal relationships 1.8 4.7
Sexual activity 5.9 4.1
Friend’s support 2.2 4.1
Respecta 6.3 2.7
Environment domain 0.87 0.0 0.2
Physical safety and security 9.0 2.9
Physical environments 8.0 4.3







Home environment 1.6 7.5





WHOQOL-BREF (TW): the short Taiwan version of the World Health
Organization Quality of Life assessment; IDU: injection drug user; aTaiwanese
national items.
Table 3 Criterion-related validity of the WHOQOL-BREF
(TW) in IDU (n = 510)
Domain Criterion measure
Overall quality of life General health
Physical health domain 0.44 0.57
Psychological health domain 0.51 0.56
Social relationships domain 0.40 0.41
Environment domain 0.52 0.49
WHOQOL-BREF (TW): the short Taiwan version of the World Health
Organization Quality of Life assessment; IDU: injection drug user. All
correlations were significant at the 0.01 levels.
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(data not shown in tables).
Validity
The Pearson’s r correlation coefficients of the 4 WHOQOL-
BREF (TW) domains and the criterion measures are shownin Table 3. All domain scores were fairly to moderately
correlated with overall QOL (0.40 ≤ r ≤ 0.52, p < 0.01) and
general health (0.41 ≤ r ≤ 0.57, p < 0.01). At the item level,
all had fair to good relationships with the aforementioned
indicators (0.20 ≤ r ≤ 0.50, p < 0.01) (data not shown in
tables) except for the pain and discomfort facet with over-
all QOL (r = 0.11) (data not shown in tables) and for the
dependence on medication or treatment facet with overall
QOL (r = 0.12) (data not shown in tables).
A summary of the selected goodness-of fit indices for
confirmatory factor analysis is presented in Table 4. The
results of the original model with CFI = 0.87, NNFI = 0.86,
and RMSEA = 0.073, indicated that the existing domain
structure with particular items did not adequately fit the
IDUs. The model reached a good fit (CFI = 0.92, NNFI =
0.91, RMSEA = 0.06) when the physical safety and security
facet (environment domain) was allowed to cross-load on
the psychological health domain and when 5 pairs of error
variances were allowed to covary (i.e., “pain and discom-
fort” and “dependence on medication or treatment”;
“positive feelings” and “spirituality, religion and per-
sonal beliefs”; “physical safety and security” and “phys-
ical environments”; “energy and fatigue” and “physical
environments”; “thinking, learning, memory and con-
centration” and “physical safety and security”). In the
final proposed model, the four first-order factors were
found to load highly and significantly on their second-
order factors (standardized loadings for physical health,
psychological health, social relationships, and environ-
ment domains were 0.93, 0.98, 0.92, and 0.88, p < 0.05,
respectively) (data not shown in tables), suggesting
adequate construct validity.
Discussion
The purpose of the current study is to examine the applic-
ability of the WHOQOL-BREF (TW) in a group of IDUs
enrolled in a MMT program. This is among the first re-
ports of psychometric properties of the WHOQOL-BREF
(TW) in this population group. Our findings suggest that
the WHOQOL-BREF (TW) had acceptable reliability (in-
ternal consistency, and corrected item-domain correl-
ation) and reasonable criterion-related validity, except for
Table 4 Goodness-of-fit indices from confirmatory factor analysis
Best suggestion χ2 RMSEA (90% CI) CFI NNFI
Original model 1093.71 0.073 (0.068 ~ 0.078) 0.87 0.86
Modified model 1 add cov (Psyc7, En8) 1025.10 0.070 (0.065 ~ 0.075) 0.89 0.87
Modified model 2 add cov (En9, Phy10) 965.93 0.067 (0.062 ~ 0.072) 0.89 0.88
Modified model 3 add cov (Phy3, Phy4) 906.85 0.064 (0.060 ~ 0.069) 0.90 0.89
Modified model 4 add cov (Psyc5, Psyc6) 856.15 0.062 (0.057 ~ 0.067) 0.91 0.90
Modified model 5 add Psyc-En8 834.17 0.061 (0.056 ~ 0.066) 0.91 0.90
Final model add cov (En8, En9) 812.49 0.060 (0.055 ~ 0.065) 0.92 0.91
RMSEA: root mean square error of approximation; CI: confidence interval; CFI: comparative fit index; NNFI: non-normed fit index.
Confirmatory factor analyses were performed while controlling for age, education, gender, HIV, HCV, duration of heroin use, methadone dose and days stayed in
MMT at study interview.
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assessing dependence on medication or treatment. Al-
though the original domain structure of the WHOQOL-
BREF (TW) did not fit the data very well, there was a good
fit after a few adjustments. Generally, the results support
the reliability and validity of the WHOQOL-BREF (TW)
for the IDU population and provide further information in
regard to the IDU’s QOL.
There were no floor or ceiling effects for the 4 do-
mains. However, the positive feelings and financial re-
sources facets showed significant floor effects. Because
hopelessness is one of the neuropsychiatric conse-
quences of HCV/HIV infection or coinfection in drug
users [34] and it has been found that most drug users
have considerable financial strain [35-37], high values of
the floor effect in the two items (i.e., “Do you enjoy your
life? and “Do you have enough money for whatever you
need?) were not unexpected. Similar to the finding in an
earlier study, we found a notable ceiling effect in the de-
pendence on the medication or treatment facet [24]. The
high level of ceiling effect in the item (i.e., “Do you need
medical treatment to cope with your daily life?”) was not
too surprising given that the majority of our study popu-
lation comprised a relatively larger number of middle-
aged participants rather than the elderly.
Cronbach’s alpha coefficients for the 4 domains of the
WHOQOL-BREF (TW) were greater than the recom-
mended standard of 0.70, indicating satisfactory internal
consistency of the instrument. This is consistent with
a prior study conducted in Iran on 115 drug addicts, in
which the alpha coefficients for 6 domains of WHOQoL-
100 ranged from .78 to .84 [38]. All the items of the
WHOQOL-BREF (TW) had item domain correlations of
0.3 or greater in our study, which were above the minimum
value of 0.2 [39], suggesting that the item had reasonable
convergence with the domain in which it is included. The
reliability of the WHOQOL-BREF (TW) was confirmed,
with the values comparable to prior results [24,25].
The validity of an instrument concerns whether a test
measures what it is intended to [40]. In the evaluation ofthe criterion-related validity, the 4 domain scores of the
WHOQOL-BREF (TW) showed statistically significant cor-
relations with the chosen criteria (i.e., overall QOL and
general health). The good associations between the physical
health, psychological health, social relationships, environ-
ment domains, and the criterion measures confirm agree-
ment but not redundancy of these QOL-specific domains.
At the item level, however, 2 items (i.e., “To what extent do
you feel that your pain prevents you in doing what you
need to do?” and “How much do you need any medical
treatment to cope with your daily life?”) showed weak
criterion-related validity with overall QOL. Similar finding
was also reported in a validation study of the Taiwanese
audio player-assisted interview version of WHOQOL-BREF
[41]. Because overall QOL involves a wide range of factors,
it is possible that an individual item, which reflects only a
narrow QOL facet, showed lower association with the cri-
terion. In addition, chronic pain is prevalent among metha-
done patients [42] and is significantly associated with
methadone daily dosage [43]. The weak relation between
pain and discomfort with general health and overall QoL
may reflect the low daily dose of methadone of our partici-
pants. Taken together, these findings lent support to the
criterion-related validity of the WHOQOL-BREF (TW) for
assessing QOL and general health in IDUs.
In regard to the construct validity of the WHOQOL-
BREF (TW), our factor-analytic results indicated a mar-
ginal acceptable model fit [44], which are in line with
the findings from several WHOQOL-BREF psychometric
studies. For instance, in 908 Polish healthy and sick re-
spondents aged 18-85, a CFI of 0.87 was reported by
Jaracz et al. [45]. Skevington et al. [46] found identical CFI
values of 0.863 and 0.864 in two random samples of over
5000 adults (mean age = 40) living in 23 countries. In ex-
ploring the factor structure of the Taiwanese version of
the WHOQOL-BREF, Yao et al. [47] showed that the ori-
ginal factor structure needed revision (CFI = 0.886). In
order to achieve a better model fit, it is necessary to add
error correlations [48]. Through covarying the error vari-
ances for items from different domains and allowing two
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showed an increase on the Bentler’s CFI from 0.85 to 0.90.
A Dutch study of women with breast cancer [49] found
that the revised model, with the additional covariances be-
tween error terms, better represented the sample data in
comparison to the initial model.
To modify the fit indices of the original model, we added
a cross-loading (physical safety and security on psycho-
logical) and 5 inter-correlations: “pain and discomfort”
with “dependence on medication or treatment”, “positive
feelings” with “spirituality, religion and personal beliefs”,
“physical safety and security” with “physical environ-
ments”, “energy and fatigue” with “physical environments”,
and “thinking, learning, memory and concentration” with
“physical safety and security”. Although the association of
the safety facet with the psychological health domain may
suggest a deviation from the theoretical measurement
structure, it informs us about the conceptualization of this
item by the drug users. The correlated residuals with re-
spect to two pairs of items suggest something in common
to these items. However, the need to correlate errors to
obtain a better-fitting model raises a question as to why
items that overlap in content are necessary in the scale.
In addition to the 2 benchmark items, the short form of
the WHOQOL-100 contains 24 items and each represents
one facet of the original form. That is, the WHOQOL-
BREF includes 24 different QOL dimensions and the fac-
tor structure of the WHOQOL-BREF is formed depending
on the correlations among the 24 QOL facets. However, it
is unlikely that the correlations between the 24 QOL di-
mensions are the same across studies because there are
differences in the demographic or clinical characteristics
of the participant groups. For example, if one considers a
subgroup of younger people and a subgroup of patients
with HIV infection, it is very likely the item “sexual activ-
ity” will be differently related to other 23 items. Although
the associations between the 24 QOL dimensions might
differ between participant groups due to various reasons,
it does not undermine the validity of the scale, but further
shows how the QOL facets may link together in a different
way. With a substantial sample size for the confirmatory
factor analysis [50], this study demonstrates that the
WHOQOL-BREF (TW) is a suitable scale for IDUs even
though a few modifications are needed.
The results of the current study need to be considered
in light of some limitations. First, because the vast major-
ity of participants were male drug users, it is not possible
to analyze whether gender has an effect on the measure-
ment of QOL in IDUs. The second limitation concerns
the generalizability of the findings. The study participants
were recruited from methadone outpatient clinics in one
geographic area and this group of injection drug users
who share not only similar drug use behaviors but also
exposure to the same modality of treatment. Thus, theresults may not be generalized to other samples recruited
from a different region. Third, our reliability evaluation of
the instrument was limited to the tests of internal
consistency. Lastly, due to the lack of specific psychological
and functional-related information about the participants,
it is not clear if such factors could have impacted the re-
sults. With these considerations in mind, this study pro-
vides good support for using the WHOQOL-BREF (TW)
in QOL assessment among drug users. More research
needs to be carried out to further examine the remaining
psychometric properties of the instrument, such as the
test-retest reliability and sensitivity to changes due to
MMT over time.
Conclusions
This is among the first studies to evaluate psychometric
characteristics of the WHOQOL-BREF (TW) in a popu-
lation of drug users. Although a few items had floor and
ceiling effects and there were slightly different patterns
found in the confirmatory factor analysis, it appears that
the WHOQOL-BREF (TW) is a reliable and valid instru-
ment to measure QOL in IDUs. The factor structure
provided by the study also helps us to understand the
QOL characteristics of the drug users in Taiwan.
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